Abstract library

29 results for "Pusceddu".
#98 Long-term follow-up analysis of lung carcinoid tumors: retrospective monoinstitutional evaluation
Introduction: Detection of prognostic factors of bronchopulmonary carcinoid (BPCs) tumors is complicated due to the rare frequency of this malignancy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Emilio Bajetta
#99 Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P)
Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)
Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Emilio Bajetta
#473 Succinate Dehydrogenase (SDHB): A New Marker of Malignancy in Midgut Carcinoids?
Introduction: The immunoistochemical (IHC) loss of SDHB expression was reported as a surrogate marker of malignancy in sporadic and familial pheocromocytomas/paragangliomas. SDHB loss is supposed to be tumorigenic (activation hypoxia signals).
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
Keywords: SDHB
#480 Immunohistochemical (IHC) Overexpression of Succinate Dehydrogenase (SDHB) as Prognostic Factor in Sporadic Pheochromocytomas/Paragangliomas (P/P)
Introduction: Recently, gene mutations (SDH complex) involved in the pathogenesis of familial P/P have been discovered. These mutations are often associated with SDHB activity loss and activation of hypoxia signals.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: MD Sara Pusceddu
#482 Well-Differentiated Neuroendocrine Tumors (WDNETs) and Carcinoid Syndrome (CS): A Retrospective Analysis of 110 Patients from Istituto Nazionale Tumori Milano
Introduction: CS is characterized by flushing, diarrhea and carcinoid heart disease (CHD) alone or in association.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Sara Pusceddu
#581 Loss of Succinate Dehydrogenase (SDHB) Expression in Midgut Carcinoids as Prognostic Factor: a New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of SDH complex have been involved in the pathogenesis of cancer cells. These mutations are often associated with loss of activity of SDH subunity B and overexpression of HIF-1a, which play a central role in angiogenesis.
Conference:
Category: Basic
Presenting Author: Dr. Massimo Milione
#645 Loss of Succinate Dehydrogenase (SDHB) in Midgut Carcinoids as Prognostic Factor: A New Marker of Personalized Cancer Medicine in Neuroendocrine Tumors?
Introduction: Gene mutations of the succinate dehydrogenase (SDH) complex are involved in the pathogenesis of cancer cells and play a pivotal role in angiogenesis and cell proliferation. The immunoistochemical (IHC) loss of SDHB is a marker of malignancy in pheocromocytomas and paragangliomas.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Md, PhD Massimo Milione
Keywords: midgut, SDHB
#646 Immunohistochemical (IHC) and Cytogenetic Approach for Improving Diagnosis and Therapy of Ewing Sarcoma (ES)/pPNET Arising in the Ileocecal Region
Introduction: ES/pPNET primary to the ileocecal region (IpPNET) have been rarely reported on and show close similarities in histology and clinical presentation with small round blue cell tumors. The EWS gene is fused to four members of the ETS family.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Md, PhD Massimo Milione
Keywords: EWS, pPnet, FEV
#648 Mammalian Target of Rapamycin (mTOR) Expression Analysis and Therapeutic Approach in Primitive (T) and Metastatic (M) Ileal Neuroendocrine Tumors (INT)
Introduction: mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine pancreatic carcinoma therapy. Because of varying behavior, INT are usually excluded from clinical trials employing the mTOR inhibitor, RAD001.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: mTor, midgut, carcinoid